PerkinElmer (PKI) Given Media Impact Rating of 0.21

News stories about PerkinElmer (NYSE:PKI) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PerkinElmer earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 47.2498421138019 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

A number of equities research analysts recently issued reports on the company. Evercore ISI assumed coverage on PerkinElmer in a research report on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 price objective on the stock. ValuEngine cut PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Robert W. Baird reissued a “buy” rating and issued a $88.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. Barclays increased their target price on PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a research note on Friday, January 26th. Finally, Cowen reissued a “hold” rating and issued a $84.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. PerkinElmer currently has an average rating of “Hold” and a consensus target price of $76.85.

PerkinElmer (PKI) traded down $0.52 on Tuesday, reaching $75.87. The company had a trading volume of 746,064 shares, compared to its average volume of 751,996. The company has a market capitalization of $8,360.00, a PE ratio of 53.81, a PEG ratio of 1.76 and a beta of 0.76. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. PerkinElmer has a 1-year low of $53.97 and a 1-year high of $84.49.

PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, January 25th. The medical research company reported $0.97 EPS for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.03. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. The business had revenue of $641.63 million for the quarter, compared to analysts’ expectations of $619.14 million. During the same quarter in the prior year, the firm earned $0.83 earnings per share. The firm’s revenue was up 13.2% on a year-over-year basis. equities research analysts predict that PerkinElmer will post 3.52 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 10th. Stockholders of record on Friday, April 13th will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, April 12th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.37%. PerkinElmer’s dividend payout ratio (DPR) is currently 19.86%.

In other news, Director Alexis P. Michas sold 5,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $73.18, for a total transaction of $365,900.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Frank Anders Wilson sold 37,535 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $70.14, for a total value of $2,632,704.90. The disclosure for this sale can be found here. Insiders have sold 59,812 shares of company stock worth $4,263,863 over the last ninety days. Insiders own 2.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with's FREE daily email newsletter.

Leave a Reply